News and Events

News

Oncologie Announces Upcoming Presentations at Investor Conferences

Waltham, MA. July 27, 2020 – Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to develop novel, targeted oncology therapies, today announced that Laura Benjamin, Ph.D., Founder and CEO of Oncologie, will be presenting a corporate overview at the following investor...

Oncologie Expands and Strengthens Management Team with Key Appointments and Promotions

Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to develop novel, targeted oncology therapies, today announced an expansion of its management team with the appointments of Matthew Osborne as Chief Financial Officer, Hagop Youssoufian, M.D., as Interim Chief Medical Officer, Bill McDonald, Ph.D., ...

Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform

Phase 2 Trial with Bavituximab in Patients with Gastric Cancer on Track to Report Preliminary Results During the Second Half of 2020. Phase 1b Trial with Navicixizumab in Patients with Ovarian Cancer Recently Presented at the Society for Gynecological Oncology Annual Meeting. Later this Year, Results from Oncologie’s Analysis Using its RNA-based Tumor...

Oncologie, Inc. Announces Collaboration with Moffitt Cancer Center to Advance the Development of Precision Medicine for the Treatment of Gastric and Gastrointestinal Cancers

Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment (TME), announced today that it has entered into a collaboration agreement with Moffitt Cancer Center. The collaboration will include genetically characterizing and classifying the microenvironment of tumors from...

Genialis and Oncologie Collaborate on Precision Medicine Initiative in Gastric Cancer

Genialis, a leader in applied data science for the development of precision medicines, today announced a collaborative partnership with Oncologie, an international, clinical-stage biopharma developing next-generation immunotherapies for cancer. Initial activities will focus on the use of Genialis’ Expressions software....

Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab

Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company,” and Oncologie, Inc. (“Oncologie”) today announced a global license agreement (the “License Agreement”) for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently being evaluated in an ongoing...

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

The initiated study will further evaluate the antitumor activity, safety and tolerability of bavituximab plus KEYTRUDA® in a gastric cancer population - Oncologie’s first global study for bavituximab plans enrollment in the US, UK, Taiwan and South Korea...

Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA® (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer

Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Oncologie's investigational drug Bavituximab,...

Oncologie Closes an $80M Series B Financing for Clinical-Stage Pipeline

Oncologie, an innovative biopharmaceutical company using proprietary biomarkers to drive clinical development of next-generation oncology therapeutics, announced today that it has closed an $80M Series B financing. Existing investors, led by Nan Fung Life Sciences and Pivotal BioVentures China, are joined by a syndicate of new investors including....

HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai, today announced the completion of a master agreement where the companies have agreed to partner on the development of...

Oncologie Launches with 16.5M USD Seed Funding Led by Pivotal bioVenture Partners China

Oncologie, an innovative biopharmaceutical company, announced today that it is launching operations in both Boston and Shanghai with $16.5M seed financing led by Pivotal bioVenture Partners China. Oncologie is committed to developing impactful cancer therapies to improve long–term survival of cancer patients worldwide...

MOLOGEN Signs License Deal for China and Global Co-Development Agreement with Oncologie for Lead Compound lefitolimod

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today the signing of a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its lead compound lefitolimod. The signed agreement is conditional upon...

Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for Avid’s phosphatidylserine (PS)-targeting program including bavituximab...

Events

LifeSci Partners Summer Symposium

10:00 – 10:25 AM ET  

BTIG Biotechnology Conference

10:00 – 10:25 AM ET

Oppenheimer Private Life Sciences Company Calls Series

2:30 – 3:05 PM ET